GLP-1 medications are a powerful tool, but they are not for everyone
Leave on for 1520 minutes
Body composition was estimated by BIA rather than measured by DEXA
For contextual class comparisons, the eMC SmPCs for semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) provide authoritative information on hypersensitivity and injection site reactions associated with approved GLP-1-based agents, and are relevant reference points for clinicians managing similar symptoms in patients receiving retatrutide in a trial setting
During shortages of Wegovy, Ozempic, Mounjaro, and Zepbound, the FDA exercised temporary enforcement discretion , allowing compounding pharmacies to help meet patient demand. Once manufacturing stabilized: Semaglutide injection products were removed from the FDA Drug Shortage List Tirzepatide injection products were formally declared resolved Compounding reverted to pre-shortage federal and state limits Broad, shortage-based compounding is no longer allowed in 2026
(2024d, February 29)
